Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Articles

Page Path
HOME > Cancer Res Treat > Volume 35(3); 2003 > Article
Review Article
Treatment of Small Cell Lung Cancer
Atsushi Horiike, Nagahiro Saijo
Cancer Research and Treatment 2003;35(3): 177-180.
DOI: https://doi.org/10.4143/crt.2003.35.3.177
Published online: June 30, 2003
Division of Internal Medicine, National Cancer CenterHospital, Tokyo, Japan.
  • 3,389 Views
  • 24 Download
  • 0 Crossref
  • 0 Scopus
prev next

Among patients with lung cancer, approximately 15% have small cell lung cancer (SCLC), SCLC is usually staged as either limited and extensive. Extensive-stage SCLC is treated primarily with chemotherapy. A recent Japanese randomized trial compared cisplatin and irinotecan (IP) with cisplatin and etoposide (EP). Patients in the IP arm did significantly better than patients in the EP arm. In the IP arm, the response rate was 84%, and the median overall survival period was 12.8 months. Limited- stage SCLC is usually treated with concurrent chemotherapy and accelerated radiation therapy, and approximately 20% of patients are cured. Future research should focus on optimizing chemotherapy regimens and radiation therapy schedules. The role of molecular targeted drugs in the treatment of SCLC must also be evaluated.

  • Cite
    CITE
    export Copy Download
    Close
    Download Citation
    Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

    Format:
    • RIS — For EndNote, ProCite, RefWorks, and most other reference management software
    • BibTeX — For JabRef, BibDesk, and other BibTeX-specific software
    Include:
    • Citation for the content below
    Treatment of Small Cell Lung Cancer
    Cancer Res Treat. 2003;35(3):177-180.   Published online June 30, 2003
    Close

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP